Metabolic And Endocrine Therapies Could Star Among US FDA’s Last 2024 Approvals

 
• By Bridget Silverman

The December calendar features nearly 20 user fee goal dates, from Novo Nordisk’s Alhemo to Lexicon’s Zynquista.

Nearly 20 drug approval decisions are due this month before FDA reviewers can put their feet up for the holiday season. (Shutterstock)

More from US FDA Performance Tracker

More from Product Reviews